Catch up on the top stories in optometry during the week of February 17-February 21.

The new first-line laser treatment for glaucoma and ocular hypertension will be unveiled at the 2025 American Glaucoma Society annual meeting in Washington, DC, from February 26 to March 2.

John Berdahl, MD, overviews the new FYXS Ocular Pressure Adjusting Pump and HERCULES trial at the Glaucoma 360 meeting.

Although 2025 is predicted to remain stable, the forecast for the optical industry still remains uncertain.

The study found that 17.4% of Medicare patients needed subspecialized procedures relative to 5.6% of surgeons practicing in rural areas between 2012 and 2022.

Ashley Wallace Tucker, OD, FAAO, FSLS, Dipl ABO, weighs in on what's on the horizon for pediatric myopia management, and provides some tips for diving into scleral lens fitting.

Prominent legislation includes the Corporate Transparency Act and last year's spending bill provision that was struck down.

The agent class’s pleiotropic effects should keep optometrists vigilant.

Shan Lin, MD, outlines a new generation of minimally invasive glaucoma surgeries (MIGS) at Glaucoma 360.

The upgraded Myopia Software Package offers comprehensive screening, ortho-k fitting, and myopia management in one device.

MonacoPro, the next evolution of Monaco from Optos, retains the powerful ultra-widefield SLO and spectral domain imaging while adding additional key product features.

Steven T. Reed, OD, talks Optometry's Meeting and public-facing initiatives that optometrists can take advantage of.

The study evaluated 13 teenagers and young adults who had high myopia (−6.50 to −9.25 D).

For Ashley Wallace Tucker, OD, FAAO, FSLS, Dipl ABO, last week's conference gives a unique opportunity for optometrists and ophthalmologists to collaborate.

Steven T. Reed, OD, American Optometric Association's president, overviews the 2024 highlights and how the organization plans to extend success into 2025.

A total of 150 placements are for aspiring optometrists to shadow SpaMedica’s clinical teams and in-house optometrists as they treat patients.

LL-BMT1 is a sustained drug delivery approach via a 3D-printed, drug-eluting contact lens to be used in glaucoma care that successfully completed a Phase 2b clinical trial.

Ashley Mills, The Vision Council CEO, outlines new additions to the show that are unveiling what is to come in terms of fashion, technology, and patient care.

At the Envision Summit 2025 in San Juan, Puerto Rico, Sherrol Reynolds, OD, FAAO, participated in a discussion on patient-centered care and the newest treatment strategies in neovascular AMD and DME.